Eisai's Eribulin Shown In Trials To Extend Breast Cancer Survival
This article was originally published in PharmAsia News
Executive Summary
Eisai's E7389 (eribulin) has demonstrated in Phase III trials it improves the survival rates of patients with metastatic breast cancer